YORBA LINDA, Calif. (PRWEB) November 15, 2018
Hepatitis C virus (HCV) is a global infection, affecting 1% of the world's population. HCV is an oncogenic virus capable of causing cirrhosis of the liver and hepatocellular carcinoma. Cirrhosis of the liver is one of the most oncogenic medical conditions, with a 10-40% risk of developing hepatocellular carcinoma at 10 years. HCV is currently an epidemic in injecting drug users, with prevalences of 70-80%.
The speaker for this webinar, Dr. Rui Tato Marinho, MD, PhD with the Faculty of Medicine at the University of Lisbon, will also share insights on how to prevent the consequences and obtain viral control (cure).
HCV has been known to exist since 1974 and was identified in 1989. The cure appeared in 2015. Innovations in the field of HCV are a fantastic and impressive success story of modern medicine. From molecular biology, ultrasound, fibroscan, hepatic transplantation, and from the bank to the patient's bedside, we were able to control and eliminate the first chronic oncogenic virus in the history of man and medicine. Still the same is not possible for hepatitis B and HIV.
With the new drugs, DAAs (Direct Antiviral Agents), in a daily intake for 8 - 12 weeks, without significant side effects, we were able to eliminate the virus in almost all patients (97%), to stop the evolution of the disease and mitigate its sometimes fatal consequences. The goal of the WHO is to eliminate Hepatitis C by 2030. This goal is only possible with the diagnosis of those who live with the virus without knowing it. Diagnostic techniques such as anti-HCV, HCVRNA and HCV Antigen are of great importance for the whole "cascade" of disease treatment.
Dr. Marinho has been practicing medicine since 1982, having a PhD in Gastroenterology in 2002. He is Associate Professor with Agregation of the University Clinic of Gastroenterology and member of the Pedagogical Council of the Faculty of Medicine of the University of Lisbon. And is head of the Department of Gastroenterology and Hepatology at the Hospital in Santa Maria. Contributions of his remarkable career include the publication of more than 93 articles in PubMed Inc. and other medical publications.
The free webinar hosted by LabRoots on November 29, 2018, will begin at 15:00pm WET, 7:00am PST; 10:00am EST. To learn more about this event, the continuing education credits offered and to register click here.
At Abbott, we're committed to helping people live their best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world – in nutrition, diagnostics, medical devices and branded generic pharmaceuticals – that create more possibilities for more people at all stages of life. Today, 99,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.
LabRoots is the leading scientific social networking website, offering top scientific trending news and premier educational virtual events and webinars. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning. We have become a primary source for trending scientific news, webinars, virtual conferences and more. Offering more than articles and webcasts that go beyond the mundane and explore the latest discoveries in the world of science, LabRoots users can stay atop their field by gaining continuing education credits from a wide range of topics through their participation in the webinars and virtual events. Join for free and become part of the largest scientific learning community in the world.